Journal
JOURNAL OF UROLOGY
Volume 184, Issue 6, Pages 2540-2548Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1016/j.juro.2010.07.030
Keywords
extracellular matrix proteins; carcinoma; renal cell; cytokines; F8 monoclonal antibody; sunitinib
Categories
Funding
- Swiss National Science Foundation
- ETH Zurich
- European Union
- Swiss Cancer League
- Swiss-Bridge Foundation
- Stammbach Foundation
- Italian Association for Cancer Research
- Fondazione Cariplo [2008-2264]
- Pfizer Germany
- Bayer
- Novartis Germany
- Wyeth Germany
- Roche Germany
- GlaxoSmithKline
Ask authors/readers for more resources
Purpose: We investigated the therapeutic action of F8-IL2, a fusion protein consisting of the F8 antibody specific to the alternatively spliced extradomain-A of fibronectin, in diabody format and of human interleukin-2 in the Caki-1 (ATCC (R)) model of human renal cell carcinoma grafted subcutaneously in nude mice. Materials and Methods: F8-IL2 was cloned, expressed in CHO cells and purified to homogeneity. This immunocytokine was administered alone or combined with 3 standard drugs commonly used as therapy for kidney cancer, including sunitinib, sorafenib and interferon-alpha, in 2 sets of doses and treatment schedules. Results: Neither F8-IL2 nor any other therapeutic agent cured tumor bearing mice when used as a single agent. The best therapeutic results were observed for the combination of sunitinib with F8-IL2 in a continuous administration schedule, which yielded a 28% cure rate and substantial tumor growth retardation. Conclusions: Considering that recombinant interleukin-2 based immunocytokines are now being investigated in several clinical trials in patients with cancer alone or combined with chemotherapy our preclinical results provide a motivation to study F8-IL2 combined with sunitinib in clinical trials in patients with kidney cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available